Lisata Therapeutics Files 8-K on Financials
Ticker: LSTA · Form: 8-K · Filed: Jun 27, 2024 · CIK: 320017
Sentiment: neutral
Topics: financial-condition, operations, company-update
Related Tickers: LISATA
TL;DR
Lisata Therapeutics (LISATA) filed an 8-K on June 27, 2024, updating its financial and operational results.
AI Summary
Lisata Therapeutics, Inc. filed an 8-K on June 27, 2024, to report on its results of operations and financial condition. The company, formerly known as Caladrius Biosciences, Inc., is incorporated in Delaware and headquartered in Basking Ridge, NJ.
Why It Matters
This filing provides an update on Lisata Therapeutics' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and operations, not indicating any immediate material adverse events.
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Registrant
- CALADRIUS BIOSCIENCES, INC. (company) — Former name
- NeoStem, Inc. (company) — Former name
- June 27, 2024 (date) — Filing date
- 110 Allen Road, Second Floor, Basking Ridge, NJ 07920 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Lisata Therapeutics, Inc.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on June 27, 2024.
What was Lisata Therapeutics, Inc. formerly known as?
Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc., and prior to that, NeoStem, Inc.
Where is Lisata Therapeutics, Inc. headquartered?
Lisata Therapeutics, Inc. is headquartered at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 896 words · 4 min read · ~3 pages · Grade level 9.6 · Accepted 2024-06-27 16:53:45
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
Filing Documents
- clbs-20240627.htm (8-K) — 26KB
- 0000320017-24-000034.txt ( ) — 150KB
- clbs-20240627.xsd (EX-101.SCH) — 2KB
- clbs-20240627_lab.xml (EX-101.LAB) — 22KB
- clbs-20240627_pre.xml (EX-101.PRE) — 13KB
- clbs-20240627_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On June 27, 2024, at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Lisata Therapeutics, Inc. (the "Company"), the stockholders voted on and approved the six proposals listed below. The following is a brief description of each matter voted upon at the Annual Meeting. For a full description of each such matter, see the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 29, 2024 (the "Proxy Statement"), as well as the final voting results with respect to each such matter: Proposal 1 . The stockholders re-elected Gregory B. Brown, M.D., Heidi Henson and David J. Mazzo, Ph.D. as Class II directors to serve until the annual meeting to be held in 2027. The final voting results with respect to Gregory B. Brown, M.D. were as follows: 3,203,590 votes for; 368,418 votes against; 25,321 votes abstaining and 2,137,358 broker non-votes. The final voting results with respect to Heidi Henson were as follows: 3,261,182 votes for; 310,709 votes against; 25,438 votes abstaining and 2,137,358 broker non-votes. The final voting results with respect to David J. Mazzo, Ph.D. were as follows: 3,151,768 votes for; 375,227 votes against; 70,334 votes abstaining and 2,137,358 broker non-votes. Proposal 2. The stockholders approved an amendment to the Lisata Therapeutics, Inc. 2018 Equity Incentive Compensation Plan to increase the number of shares of common stock that may be issued under the Plan by 600,000. The final voting results with respect to this Proposal were as follows: 2,606,756 votes for; 588,819 votes against; 401,754 votes abstaining and 2,137,358 broker non-votes. Proposal 3. The stockholders approved an amendment to the 2018 Equity Incentive Compensation Plan to add a three-year "evergreen" provision whereby the number of shares available for issuance will be increased for three consecutive years, beginning on January 1, 2025, in
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LISATA THERAPEUTICS, INC. By: /s/ David J. Mazzo Name: David J. Mazzo, PhD Title: President & Chief Executive Officer Dated: June 27, 2024